eIF4B Inhibitors are a class of compounds that target the eukaryotic initiation factor 4B (eIF4B), a critical component of the translation initiation machinery in eukaryotic cells. eIF4B plays a key role in facilitating the recruitment of ribosomes to messenger RNA (mRNA), a process that is essential for the synthesis of proteins. Specifically, eIF4B enhances the helicase activity of eIF4A, another initiation factor, which unwinds secondary structures in the 5' untranslated region (UTR) of mRNA. This unwinding is necessary for the small ribosomal subunit to scan the mRNA and locate the start codon, thereby initiating translation. Inhibitors of eIF4B disrupt this process, potentially leading to a reduction in global protein synthesis, as well as selective effects on the translation of specific mRNAs that are particularly dependent on eIF4B activity.
Research into eIF4B Inhibitors is valuable for understanding the regulation of translation, a fundamental process that controls gene expression at the post-transcriptional level. By inhibiting eIF4B, scientists can investigate the effects on mRNA translation, especially those mRNAs with complex secondary structures in their 5' UTRs, which are more reliant on eIF4B for efficient translation. This can provide insights into how cells control the synthesis of proteins in response to various stimuli and conditions, such as stress, nutrient availability, and signaling pathways. Additionally, eIF4B is known to interact with other components of the translation initiation complex, including eIF3 and the cap-binding protein eIF4E, so its inhibition may shed light on the broader network of interactions that regulate translation initiation. Understanding these interactions is crucial for unraveling the complexities of translational control and its impact on cellular function, growth, and adaptation. Researchers can use eIF4B Inhibitors as tools to dissect these processes, thereby contributing to a deeper knowledge of how cells regulate protein production in both normal and altered states.
Items 11 to 16 of 16 total
디스플레이 라벨:
제품명 | CAS # | 카탈로그 번호 | 수량 | 가격 | 引用 | RATING |
---|---|---|---|---|---|---|
Doxorubicin | 23214-92-8 | sc-280681 sc-280681A | 1 mg 5 mg | $173.00 $418.00 | 43 | |
독소루비신으로 인한 DNA 손상은 세포가 정상적인 기능보다 DNA 복구에 우선순위를 두게 하여 잠재적으로 RNAi 메커니즘을 억제하고 eIF2C2 수치를 감소시킬 수 있습니다. | ||||||
Camptothecin | 7689-03-4 | sc-200871 sc-200871A sc-200871B | 50 mg 250 mg 100 mg | $57.00 $182.00 $92.00 | 21 | |
캠토테신과 프라임이 토포이소머라제 I을 억제하면 DNA 손상이 발생하여 RNAi 과정에 대한 집중력이 감소하고 결과적으로 eIF2C2 발현이 감소할 수 있습니다. | ||||||
Geldanamycin | 30562-34-6 | sc-200617B sc-200617C sc-200617 sc-200617A | 100 µg 500 µg 1 mg 5 mg | $38.00 $58.00 $102.00 $202.00 | 8 | |
겔다나마이신은 Hsp90을 억제함으로써 RNAi와 관련된 단백질을 불안정하게 만들 수 있으며, 이는 eIF2C2 안정성 또는 합성의 감소를 포함할 수 있습니다. | ||||||
Silvestrol | 697235-38-4 | sc-507504 | 1 mg | $920.00 | ||
식물 아글레이아 포베올라타에서 분리한 천연 화합물로, EIF4AI를 강력하게 억제하는 것으로 알려져 있습니다. | ||||||
Rocaglamide | 84573-16-0 | sc-203241 sc-203241A sc-203241B sc-203241C sc-203241D | 100 µg 1 mg 5 mg 10 mg 25 mg | $270.00 $465.00 $1607.00 $2448.00 $5239.00 | 4 | |
아글레이아 속과 같은 여러 식물에서 발견되는 또 다른 천연 화합물로 강력한 EIF4AI 억제 활성을 가지고 있습니다. | ||||||
4E1RCat | 328998-25-0 | sc-361085 sc-361085A | 10 mg 50 mg | $189.00 $797.00 | ||
eIF4F 복합체를 파괴하여 캡 의존적 번역을 억제하도록 설계된 합성 EIF4AI 억제제입니다. |